Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Potential protective role of Grainyhead-like genes in the development of clear cell renal cell carcinoma.

Pawlak M, Kikulska A, Wrzesinski T, Rausch T, Kwias Z, Wilczynski B, Benes V, Wesoly J, Wilanowski T.

Mol Carcinog. 2017 Nov;56(11):2414-2423. doi: 10.1002/mc.22682. Epub 2017 Jun 15.

PMID:
28543713
2.

Mutations in proteasome-related genes are associated with thyroid hemiagenesis.

Budny B, Szczepanek-Parulska E, Zemojtel T, Szaflarski W, Rydzanicz M, Wesoly J, Handschuh L, Wolinski K, Piatek K, Niedziela M, Ziemnicka K, Figlerowicz M, Zabel M, Ruchala M.

Endocrine. 2017 May;56(2):279-285. doi: 10.1007/s12020-017-1287-4. Epub 2017 Apr 7.

3.

Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA.

Kluzek K, Srebniak MI, Majer W, Ida A, Milecki T, Huminska K, van der Helm RM, Silesian A, Wrzesinski TM, Wojciechowicz J, Beverloo BH, Kwias Z, Bluyssen HAR, Wesoly J.

Oncotarget. 2017 Apr 25;8(17):28558-28574. doi: 10.18632/oncotarget.15331.

4.

Targeted inhibition of STATs and IRFs as a potential treatment strategy in cardiovascular disease.

Szelag M, Piaszyk-Borychowska A, Plens-Galaska M, Wesoly J, Bluyssen HA.

Oncotarget. 2016 Jul 26;7(30):48788-48812. doi: 10.18632/oncotarget.9195. Review.

5.

The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses.

Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HA.

Cytokine Growth Factor Rev. 2016 Jun;29:71-81. doi: 10.1016/j.cytogfr.2016.02.010. Epub 2016 Mar 18.

6.

STAT1 and IRF8 in Vascular Inflammation and Cardiovascular Disease: Diagnostic and Therapeutic Potential.

Chmielewski S, Piaszyk-Borychowska A, Wesoly J, Bluyssen HA.

Int Rev Immunol. 2016 Sep 2;35(5):434-454. Epub 2015 Nov 25.

PMID:
26606328
7.

Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases.

Szelag M, Wesoly J, Bluyssen HA.

Curr Protein Pept Sci. 2016;17(2):135-46. Review.

PMID:
26521960
8.

Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors.

Wrzesiński T, Szelag M, Cieślikowski WA, Ida A, Giles R, Zodro E, Szumska J, Poźniak J, Kwias Z, Bluyssen HA, Wesoly J.

BMC Cancer. 2015 Jul 14;15:518. doi: 10.1186/s12885-015-1530-4.

9.

Consequences of the loss of the Grainyhead-like 1 gene for renal gene expression, regulation of blood pressure and heart rate in a mouse model.

Pawlak M, Walkowska A, Mlącki M, Pistolic J, Wrzesiński T, Benes V, Jane SM, Wesoły J, Kompanowska-Jezierska E, Wilanowski T.

Acta Biochim Pol. 2015;62(2):287-96. doi: 10.18388/abp.2015_1001. Epub 2015 Apr 21.

10.

Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.

Szelag M, Czerwoniec A, Wesoly J, Bluyssen HA.

PLoS One. 2015 Feb 24;10(2):e0116688. doi: 10.1371/journal.pone.0116688. eCollection 2015.

11.

STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1.

Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen YL, Chmielewski S, Kostyrko K, Wesoly J, Balint BL, Lee CK, Bluyssen HA.

Biochem J. 2015 Mar 15;466(3):511-24. doi: 10.1042/BJ20140644.

12.

The epigenetic landscape of clear-cell renal cell carcinoma.

Kluzek K, Bluyssen HA, Wesoly J.

J Kidney Cancer VHL. 2015 May 28;2(3):90-104. doi: 10.15586/jkcvhl.2015.33. eCollection 2015.

13.

STAT1-dependent signal integration between IFNγ and TLR4 in vascular cells reflect pro-atherogenic responses in human atherosclerosis.

Chmielewski S, Olejnik A, Sikorski K, Pelisek J, Błaszczyk K, Aoqui C, Nowicka H, Zernecke A, Heemann U, Wesoly J, Baumann M, Bluyssen HA.

PLoS One. 2014 Dec 5;9(12):e113318. doi: 10.1371/journal.pone.0113318. eCollection 2014.

14.

Data mining of atherosclerotic plaque transcriptomes predicts STAT1-dependent inflammatory signal integration in vascular disease.

Sikorski K, Wesoly J, Bluyssen HA.

Int J Mol Sci. 2014 Aug 18;15(8):14313-31. doi: 10.3390/ijms150814313.

15.

Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.

Szeląg M, Czerwoniec A, Wesoly J, Bluyssen HA.

Eur J Pharmacol. 2014 Oct 5;740:417-20. doi: 10.1016/j.ejphar.2014.05.047. Epub 2014 Jun 2.

PMID:
25183399
16.

Molecular properties and medical applications of peptide nucleic acids.

Malcher J, Wesoły J, Bluyssen HA.

Mini Rev Med Chem. 2014 May;14(5):401-10. Review.

PMID:
24766383
17.

FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data.

Zodro E, Jaroszewski M, Ida A, Wrzesiński T, Kwias Z, Bluyssen H, Wesoly J.

Tumour Biol. 2014 Mar;35(3):2607-17. doi: 10.1007/s13277-013-1344-4. Epub 2013 Dec 8.

18.

In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.

Szelag M, Sikorski K, Czerwoniec A, Szatkowska K, Wesoly J, Bluyssen HA.

Eur J Pharmacol. 2013 Nov 15;720(1-3):38-48. doi: 10.1016/j.ejphar.2013.10.055. Epub 2013 Nov 6.

PMID:
24211327
19.

STAT1 as a central mediator of IFNγ and TLR4 signal integration in vascular dysfunction.

Sikorski K, Chmielewski S, Olejnik A, Wesoly JZ, Heemann U, Baumann M, Bluyssen H.

JAKSTAT. 2012 Oct 1;1(4):241-9. doi: 10.4161/jkst.22469. Review.

20.

Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications.

Rydzanicz M, Wrzesiński T, Bluyssen HA, Wesoły J.

Cancer Lett. 2013 Dec 1;341(2):111-26. doi: 10.1016/j.canlet.2013.08.006. Epub 2013 Aug 7. Review.

PMID:
23933176

Supplemental Content

Loading ...
Support Center